You need to be logged in to view this video

Heart Disease, Stroke, Parkinson's Disease: Is Therapeutic Angiogenesis a New Medical Breakthrough Treatment?

Released on Wednesday, November 18, 2020•BIOTECH

Share
Facebook Twitter LinkedIn SMS

Learn about FDA Clinical Trials where revolutionary new treatment addresses—what Zhittya Genesis Medicine believes—the cause of the disease and not just symptoms. Zhittyas research is based on thousands of scientific papers and decades of studies. Find out about a new disease modifying agent that potentially reverses the cause of the illness.

Jack Jacobs

Zhittya Genesis Medicine, Inc., President and Chief Scientific Officer

Dr. Jack Jacobs has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations, as well as the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of biological chemistry at Merck and for 15 years worked with Mr. Daniel Montano as cardiovascular biotherapeutics' chief scientific officer. Dr. Jacobs oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers, and peripheral artery disease. He also oversaw the manufacturing of clinical lots of FGF-1 that were used in those clinical studies. Dr. Jacobs received a BS degree from Davidson College and a PhD in molecular biology from Washington University, St. Louis.